Knowledge and malaria treatment practices using artemisinin combination therapy (ACT) in Malawi: survey of health professionals

Malaria Journal

Research

Linda V Kalilani-Phiri¹  Douglas Lungu²  Renia Coghlan³ 

[1] College of Medicine, University of Malawi, Private Bag 360, Blantyre 3, Malawi;Daeyang Luke Hospital, P.O. Box 30330, Lilongwe 3, Malawi;Medicines for Malaria Venture, Geneva, Switzerland;

关键词: Malaria;    Health Care Professional;    Treatment Guideline;    Treatment Policy;    Severe Malaria;   

DOI  :  10.1186/1475-2875-10-279

 received in 2011-05-12, accepted in 2011-09-22,  发布年份 2011

来源: Springer

【 摘 要 】

BackgroundMalaria still remains a life-threatening disease worldwide causing between 190 and 311 million cases of malaria in 2008. Due to increased resistance to sulphadoxine-pyrimethamine (SP), the Ministry of Health in Malawi, as in many sub-Saharan African countries, changed the malaria treatment policy to use artemisinin-based combination therapy (ACT). In order to optimize the correct use of this drug, and protect against the development of the parasite's resistance, it is important to assess the knowledge and practices of medical practitioners on the use of ACT and its impact on adherence to new treatment policy guidelines.MethodsA cross-sectional survey was conducted to assess the knowledge and perceptions of Malawian medical doctors and pharmacists on the use of ACT and the drivers of treatment choice and clinical treatment decisions. Medical doctors and pharmacists who are involved in managing malaria patients in Malawi were recruited and a self-administered questionnaire was used to obtain information on socio-demographic characteristics of the study participants, knowledge on ACT, source of information on ACT and methods used to decide on the treatment of patients with malaria.ResultsMost of the participants (95.7%) know at least one form of ACT, 67.4% reported that different forms of ACT have different characteristics, 77.3% reported that there are special formulations for children. The most commonly mentioned ACT was artemether-lumefantrine (AL), by 94.6% of the participants and 75.0% of the participants indicated that they prefer to prescribe AL. 73.9% of participants had ever received information on ACT. However, only 31.5% had received training on management of malaria using ACT. There were 71.7% respondents who had heard of ACT causing side effects. Only 25.0% of the participants had received training on how to report SAEs.ConclusionIt was found that most of the participants know about ACT and treatment guidelines for malaria. However, most of the participants have not received any training on how to use ACT and how to report adverse effects arising from the use of ACT. There is need for more training of health care professionals to ensure correct and effective use of ACT.

【 授权许可】

CC BY   
© Kalilani-Phiri et al; licensee BioMed Central Ltd. 2011